SRXH
SRx Health Solutions Inc.
Drug Manufacturers - General
Market Cap$1M
5Y Perf.-94.2%
Compare Stocks
4 / 10Try these comparisons:
Stock Comparison
SRXH vs PHVS vs KALV vs OPRX
Revenue, margins, valuation, and 5-year total return — side by side.
PHVS
Pharvaris N.V.
Biotechnology
Market Cap$1.93B
5Y Perf.+60.6%
KALV
KalVista Pharmaceuticals, Inc.
Biotechnology
Market Cap$1.37B
5Y Perf.+94.0%
OPRX
OptimizeRx Corporation
Medical - Healthcare Information Services
Market Cap$124M
5Y Perf.-27.3%
SRXH vs PHVS vs KALV vs OPRX — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | SRXH | PHVS | KALV | OPRX |
|---|---|---|---|---|
| Industry | Drug Manufacturers - General | Biotechnology | Biotechnology | Medical - Healthcare Information Services |
| Market Cap | $1M | $1.93B | $1.37B | $124M |
| Revenue (TTM) | $119M | $0.00 | $15M | $109M |
| Net Income (TTM) | $-11M | $-166M | $-210M | $5M |
| Gross Margin | 19.9% | — | -17.2% | 67.3% |
| Operating Margin | -4.9% | — | -13.4% | 10.7% |
| Forward P/E | — | — | — | 7.0x |
| Total Debt | $39M | $861K | $6M | $5M |
| Cash & Equiv. | $2M | $281M | $99M | $23M |
SRXH vs PHVS vs KALV vs OPRX — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
SRXH
PHVS
KALV
OPRX
| Stock | Apr 25 | May 26 | Return |
|---|---|---|---|
| SRx Health Solution… (SRXH) | 100 | 5.8 | -94.2% |
| Pharvaris N.V. (PHVS) | 100 | 160.6 | +60.6% |
| KalVista Pharmaceut… (KALV) | 100 | 194.0 | +94.0% |
| OptimizeRx Corporat… (OPRX) | 100 | 72.7 | -27.3% |
Price return only. Dividends and distributions are not included.
Quick Verdict: SRXH vs PHVS vs KALV vs OPRX
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: SRXH and KALV are tied at the top with 2 categories each — the right choice depends on your priorities. KalVista Pharmaceuticals, Inc. is the stronger pick specifically for capital preservation and lower volatility and recent price momentum and sentiment. OPRX also leads in specific categories worth noting. As sector peers, any of these can serve as alternatives in the same allocation.
SRXH
SRx Health Solutions Inc.
The Growth Play
SRXH has the current edge in this matchup, primarily because of its strength in growth exposure.
- Rev growth 28.4%, EPS growth 74.1%
- 28.4% revenue growth vs KALV's -34.5%
- Better valuation composite
Best for: growth exposure
PHVS
Pharvaris N.V.
The Defensive Pick
PHVS is the clearest fit if your priority is sleep-well-at-night.
- Lower volatility, beta 1.02, Low D/E 0.3%, current ratio 12.60x
Best for: sleep-well-at-night
KALV
KalVista Pharmaceuticals, Inc.
The Income Pick
KALV is the #2 pick in this set and the best alternative if income & stability and long-term compounding is your priority.
- beta 0.82
- 154.5% 10Y total return vs PHVS's 2.3%
- Beta 0.82, current ratio 5.35x
- Beta 0.82 vs OPRX's 2.28
Best for: income & stability and long-term compounding
OPRX
OptimizeRx Corporation
The Quality Compounder
OPRX is the clearest fit if your priority is quality and efficiency.
- 4.7% margin vs KALV's -13.9%
- 3.0% ROA vs KALV's -77.7%, ROIC 7.1% vs -152.3%
Best for: quality and efficiency
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | SRXH | 28.4% revenue growth vs KALV's -34.5% |
| Value | SRXH | Better valuation composite |
| Quality / Margins | OPRX | 4.7% margin vs KALV's -13.9% |
| Stability / Safety | KALV | Beta 0.82 vs OPRX's 2.28 |
| Dividends | Tie | None of these 4 stocks pay a meaningful dividend |
| Momentum (1Y) | KALV | +118.1% vs SRXH's -84.6% |
| Efficiency (ROA) | OPRX | 3.0% ROA vs KALV's -77.7%, ROIC 7.1% vs -152.3% |
SRXH vs PHVS vs KALV vs OPRX — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLOPRXLAGGINGKALV
Who Leads Where
OPRX leads in 2 of 6 categories
SRXH leads 1 • PHVS leads 0 • KALV leads 0 • 2 tied
Explore the data ↓KALVKalVista Pharmaceutic…
0leads
PHVSPharvaris N.V.
0leads
SRXHSRx Health Solutions …
1leads
OPRXOptimizeRx Corporation
2leads
6 Total Categories
CATEGORYLEADERvs SRXHvs PHVSMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
OPRX4/5
Valuation MetricsMultiples, price ratios, and targets
SRXH2/4
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
OPRX6/9
Total Returns1Y, 3Y, 5Y total returns with dividends
Tied
—
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
OPRX leads this category, winning 4 of 5 comparable metrics.
Income & Cash Flow (Last 12 Months)
SRXH and PHVS operate at a comparable scale, with $119M and $0 in trailing revenue. OPRX is the more profitable business, keeping 4.7% of every revenue dollar as net income compared to KALV's -13.9%.
| Metric | SRXHSRx Health Soluti… | PHVSPharvaris N.V. | KALVKalVista Pharmace… | OPRXOptimizeRx Corpor… |
|---|---|---|---|---|
| RevenueTrailing 12 months | $119M | $0 | $15M | $109M |
| EBITDAEarnings before interest/tax | — | -$86M | -$202M | $16M |
| Net IncomeAfter-tax profit | — | -$166M | -$210M | $5M |
| Free Cash FlowCash after capex | — | -$134M | -$160M | $12M |
| Gross MarginGross profit ÷ Revenue | +19.9% | — | -17.2% | +67.3% |
| Operating MarginEBIT ÷ Revenue | -4.9% | — | -13.4% | +10.7% |
| Net MarginNet income ÷ Revenue | -9.4% | — | -13.9% | +4.7% |
| FCF MarginFCF ÷ Revenue | +1.3% | — | -10.6% | +10.6% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | — | — | -0.2% |
| EPS Growth (YoY)Latest quarter vs prior year | — | +22.1% | -1.1% | — |
OPRX leads this category, winning 4 of 5 comparable metrics.
Valuation Metrics
SRXH leads this category, winning 2 of 4 comparable metrics.
Valuation Metrics
| Metric | SRXHSRx Health Soluti… | PHVSPharvaris N.V. | KALVKalVista Pharmace… | OPRXOptimizeRx Corpor… |
|---|---|---|---|---|
| Market CapShares × price | $1M | $1.9B | $1.4B | $124M |
| Enterprise ValueMkt cap + debt − cash | $29M | $1.6B | $1.3B | $105M |
| Trailing P/EPrice ÷ TTM EPS | -0.17x | -10.18x | -7.24x | 24.56x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — | — | 7.04x |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — |
| EV / EBITDAEnterprise value multiple | — | — | — | 6.55x |
| Price / SalesMarket cap ÷ Revenue | 0.02x | — | — | 1.13x |
| Price / BookPrice ÷ Book value/share | — | 5.10x | 13.91x | 0.98x |
| Price / FCFMarket cap ÷ FCF | 1.20x | — | — | 6.62x |
SRXH leads this category, winning 2 of 4 comparable metrics.
Profitability & Efficiency
OPRX leads this category, winning 6 of 9 comparable metrics.
Profitability & Efficiency
OPRX delivers a 4.2% return on equity — every $100 of shareholder capital generates $4 in annual profit, vs $-3 for KALV. PHVS carries lower financial leverage with a 0.00x debt-to-equity ratio, signaling a more conservative balance sheet compared to KALV's 0.07x. On the Piotroski fundamental quality scale (0–9), OPRX scores 8/9 vs PHVS's 1/9, reflecting strong financial health.
| Metric | SRXHSRx Health Soluti… | PHVSPharvaris N.V. | KALVKalVista Pharmace… | OPRXOptimizeRx Corpor… |
|---|---|---|---|---|
| ROE (TTM)Return on equity | — | -53.2% | -2.8% | +4.2% |
| ROA (TTM)Return on assets | -22.4% | -49.0% | -77.7% | +3.0% |
| ROICReturn on invested capital | -18.1% | — | -152.3% | +7.1% |
| ROCEReturn on capital employed | -98.8% | -44.7% | -89.9% | +7.6% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 1 | 2 | 8 |
| Debt / EquityFinancial leverage | — | 0.00x | 0.07x | 0.04x |
| Net DebtTotal debt minus cash | $37M | -$280M | -$92M | -$19M |
| Cash & Equiv.Liquid assets | $2M | $281M | $99M | $23M |
| Total DebtShort + long-term debt | $39M | $861,470 | $6M | $5M |
| Interest CoverageEBIT ÷ Interest expense | -2.83x | — | -13.75x | 1.26x |
OPRX leads this category, winning 6 of 9 comparable metrics.
Total Returns (Dividends Reinvested)
Evenly matched — PHVS and KALV each lead in 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in PHVS five years ago would be worth $13,115 today (with dividends reinvested), compared to $536 for SRXH. Over the past 12 months, KALV leads with a +118.1% total return vs SRXH's -84.6%. The 3-year compound annual growth rate (CAGR) favors PHVS at 47.4% vs SRXH's -62.3% — a key indicator of consistent wealth creation.
| Metric | SRXHSRx Health Soluti… | PHVSPharvaris N.V. | KALVKalVista Pharmace… | OPRXOptimizeRx Corpor… |
|---|---|---|---|---|
| YTD ReturnYear-to-date | -52.9% | +12.1% | +72.8% | -46.6% |
| 1-Year ReturnPast 12 months | -84.6% | +73.6% | +118.1% | -30.1% |
| 3-Year ReturnCumulative with dividends | -94.6% | +220.5% | +180.1% | -54.4% |
| 5-Year ReturnCumulative with dividends | -94.6% | +31.2% | +5.9% | -87.3% |
| 10-Year ReturnCumulative with dividends | -94.6% | +2.3% | +154.5% | +110.5% |
| CAGR (3Y)Annualised 3-year return | -62.3% | +47.4% | +41.0% | -23.0% |
Evenly matched — PHVS and KALV each lead in 3 of 6 comparable metrics.
Risk & Volatility
Evenly matched — SRXH and KALV each lead in 1 of 2 comparable metrics.
Risk & Volatility
SRXH is the less volatile stock with a -0.32 beta — it tends to amplify market swings less than OPRX's 2.28 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. KALV currently trades 99.5% from its 52-week high vs SRXH's 9.0% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | SRXHSRx Health Soluti… | PHVSPharvaris N.V. | KALVKalVista Pharmace… | OPRXOptimizeRx Corpor… |
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | -0.32x | 1.02x | 0.82x | 2.28x |
| 52-Week HighHighest price in past year | $1.25 | $31.12 | $26.84 | $22.25 |
| 52-Week LowLowest price in past year | $0.08 | $14.59 | $9.83 | $5.54 |
| % of 52W HighCurrent price vs 52-week peak | +9.0% | +95.4% | +99.5% | +29.8% |
| RSI (14)Momentum oscillator 0–100 | 41.4 | 57.2 | 75.4 | 46.9 |
| Avg Volume (50D)Average daily shares traded | 22.0M | 227K | 3.0M | 476K |
Evenly matched — SRXH and KALV each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: PHVS as "Buy", KALV as "Buy", OPRX as "Buy". Consensus price targets imply 156.4% upside for OPRX (target: $17) vs 6.7% for KALV (target: $29).
| Metric | SRXHSRx Health Soluti… | PHVSPharvaris N.V. | KALVKalVista Pharmace… | OPRXOptimizeRx Corpor… |
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | — | $43.67 | $28.50 | $17.00 |
| # AnalystsCovering analysts | — | 11 | 13 | 15 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — |
| Dividend StreakConsecutive years of raises | — | — | — | 1 |
| Dividend / ShareAnnual DPS | — | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
OPRX leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). SRXH leads in 1 (Valuation Metrics). 2 tied.
Best OverallOptimizeRx Corporation (OPRX)Leads 2 of 6 categories
Loading custom metrics...
SRXH vs PHVS vs KALV vs OPRX: Key Questions Answered
9 questions · data-driven answers · updated daily
01Is SRXH or PHVS or KALV or OPRX a better buy right now?
For growth investors, SRx Health Solutions Inc.
(SRXH) is the stronger pick with 28. 4% revenue growth year-over-year, versus 18. 8% for OptimizeRx Corporation (OPRX). OptimizeRx Corporation (OPRX) offers the better valuation at 24. 6x trailing P/E (7. 0x forward), making it the more compelling value choice. Analysts rate Pharvaris N. V. (PHVS) a "Buy" — based on 11 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — SRXH or PHVS or KALV or OPRX?
Over the past 5 years, Pharvaris N.
V. (PHVS) delivered a total return of +31. 2%, compared to -94. 6% for SRx Health Solutions Inc. (SRXH). Over 10 years, the gap is even starker: KALV returned +154. 5% versus SRXH's -94. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — SRXH or PHVS or KALV or OPRX?
By beta (market sensitivity over 5 years), SRx Health Solutions Inc.
(SRXH) is the lower-risk stock at -0. 32β versus OptimizeRx Corporation's 2. 28β — meaning OPRX is approximately -805% more volatile than SRXH relative to the S&P 500. On balance sheet safety, Pharvaris N. V. (PHVS) carries a lower debt/equity ratio of 0% versus 7% for KalVista Pharmaceuticals, Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — SRXH or PHVS or KALV or OPRX?
By revenue growth (latest reported year), SRx Health Solutions Inc.
(SRXH) is pulling ahead at 28. 4% versus 18. 8% for OptimizeRx Corporation (OPRX). On earnings-per-share growth, the picture is similar: OptimizeRx Corporation grew EPS 124. 5% year-over-year, compared to -7. 3% for KalVista Pharmaceuticals, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — SRXH or PHVS or KALV or OPRX?
OptimizeRx Corporation (OPRX) is the more profitable company, earning 4.
7% net margin versus -1391. 1% for KalVista Pharmaceuticals, Inc. — meaning it keeps 4. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: OPRX leads at 10. 7% versus -1343. 0% for KALV. At the gross margin level — before operating expenses — OPRX leads at 67. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Is SRXH or PHVS or KALV or OPRX more undervalued right now?
Analyst consensus price targets imply the most upside for OPRX: 156.
4% to $17. 00.
07Which pays a better dividend — SRXH or PHVS or KALV or OPRX?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
08Is SRXH or PHVS or KALV or OPRX better for a retirement portfolio?
For long-horizon retirement investors, SRx Health Solutions Inc.
(SRXH) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0. 32)). OptimizeRx Corporation (OPRX) carries a higher beta of 2. 28 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (SRXH: -94. 6%, OPRX: +110. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between SRXH and PHVS and KALV and OPRX?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: SRXH is a small-cap high-growth stock; PHVS is a small-cap quality compounder stock; KALV is a small-cap quality compounder stock; OPRX is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.